BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 26658770)

  • 1. Temsirolimus acts as additive with bendamustine in aggressive lymphoma.
    Zoellner AK; Weiglein T; Hutter G; Zimmermann Y; Cieplik HC; Hess G; Dreyling M
    Ann Hematol; 2016 Feb; 95(3):403-7. PubMed ID: 26658770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma.
    Yazbeck VY; Buglio D; Georgakis GV; Li Y; Iwado E; Romaguera JE; Kondo S; Younes A
    Exp Hematol; 2008 Apr; 36(4):443-50. PubMed ID: 18343280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma.
    Hess G; Keller U; Scholz CW; Witzens-Harig M; Atta J; Buske C; Kirschey S; Ruckes C; Medler C; van Oordt C; Klapper W; Theobald M; Dreyling M
    Leukemia; 2015 Aug; 29(8):1695-701. PubMed ID: 25765545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
    Munakata W; Tobinai K
    Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
    Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
    Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.
    Ogura M; Ishizawa K; Maruyama D; Uike N; Ando K; Izutsu K; Terui Y; Imaizumi Y; Tsukasaki K; Suzuki K; Izumi T; Usuki K; Kinoshita T; Taniwaki M; Uoshima N; Suzumiya J; Kurosawa M; Nagai H; Uchida T; Fukuhara N; Choi I; Ohmachi K; Yamamoto G; Tobinai K;
    Int J Hematol; 2017 Apr; 105(4):470-477. PubMed ID: 27900638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.
    Hess G; Smith SM; Berkenblit A; Coiffier B
    Semin Oncol; 2009 Dec; 36 Suppl 3():S37-45. PubMed ID: 19963099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
    Czuczman MS; Goy A; Lamonica D; Graf DA; Munteanu MC; van der Jagt RH
    Ann Hematol; 2015 Dec; 94(12):2025-32. PubMed ID: 26411584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B7-H3 silencing inhibits tumor progression of mantle cell lymphoma and enhances chemosensitivity.
    Zhang W; Wang Y; Wang J; Dong F; Zhu M; Wan W; Li H; Wu F; Yan X; Ke X
    Int J Oncol; 2015; 46(6):2562-72. PubMed ID: 25872657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas.
    Chen D; Mao C; Zhou Y; Su Y; Liu S; Qi WQ
    Int J Oncol; 2016 Jan; 48(1):253-60. PubMed ID: 26549638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
    Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
    Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
    Hsiao LT; Tien HF; Kuo CY; Wu JH; Hou HA; Wang MC; Liu CY; Chen PM; Chiou TJ
    Hematol Oncol; 2015 Dec; 33(4):136-44. PubMed ID: 25111959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab.
    Cencini E; Sicuranza A; Fabbri A; Ferrigno I; Rigacci L; Cox MC; Raspadori D; Bocchia M
    Br J Haematol; 2019 Jan; 184(2):223-231. PubMed ID: 30203425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy and management of temsirolimus in patients with relapsed or refractory mantle cell lymphoma.
    Coiffier B
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):351-9. PubMed ID: 23763923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines.
    Visco C; Castegnaro S; Chieregato K; Bernardi M; Albiero E; Zanon C; Madeo D; Rodeghiero F
    Blood Cells Mol Dis; 2012 Jan; 48(1):68-75. PubMed ID: 22036761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.
    Matsumoto Y; Kobayashi T; Shimura Y; Kawata E; Nagoshi H; Ohshiro M; Sugitani M; Shimura K; Iwai T; Fuchida SI; Yoshida M; Kiyota M; Mizutani S; Chinen Y; Takimoto-Shimomura T; Nakao M; Kaneko H; Uchiyama H; Uoshima N; Nishigaki H; Kobayashi Y; Horiike S; Shimazaki C; Taniwaki M; Kuroda J;
    Int J Hematol; 2019 Jul; 110(1):77-85. PubMed ID: 31127456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness of Chemotherapy, Rituximab, and Bendamustine in Medicare Beneficiaries With Mantle-Cell Lymphoma.
    Fu S; Wang M; Zhao H; Li R; Lairson DR; Giordano SH; Zhao B; Du XL
    Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):e616-e623. PubMed ID: 31563564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rare composite lymphoma: follicular and in situ mantle cell.
    Marí-Jimenez P; Martínez-Losada C; Centeno-Haro M; Rodríguez-García G; Perez-Seoane C; Sánchez-García J
    Ann Hematol; 2016 Aug; 95(8):1351-2. PubMed ID: 27103006
    [No Abstract]   [Full Text] [Related]  

  • 19. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.
    Zaja F; Ferrero S; Stelitano C; Ferrari A; Salvi F; Arcari A; Musuraca G; Botto B; Spina M; Cellini C; Patti C; Liberati AM; Minotto C; Pileri SA; Ceccarelli M; Volpetti S; Ferranti A; Drandi D; Montechiarello E; Ladetto M; Carmichael J; Fanin R
    Haematologica; 2017 May; 102(5):e203-e206. PubMed ID: 28082342
    [No Abstract]   [Full Text] [Related]  

  • 20. Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects.
    Bouabdallah K; Ribrag V; Terriou L; Soria JC; Delarue R
    Curr Opin Oncol; 2013 Mar; 25 Suppl 2():S1-12. PubMed ID: 23388840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.